Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Hannah Goulart, Elias Jabbour, Nitin Jain, Farhad Ravandi, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alex Bataller, Fadi Haddad, Rita Khouri, Jayastu Senapati, Rebecca Garris, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2025-3350

Published: 2025

Journal Articles

Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission

Hannah Goulart, Elias Jabbour, Nitin Jain, Fadi Haddad, Jayastu Senapati, Rita Khouri, Guillermo Garcia-Manero, William Wierda, Farhad Ravandi, Naveen Pemmaraju, Kelly Chien, Rebecca Garris, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 3348.

https://doi.org/10.1182/blood-2025-3348

Published: 2025

Journal Articles

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Jayastu Senapati, Elias Jabbour, Nitin Jain, Kelly Chien, Musa Yilmaz, Fadi Haddad, Guillermo Montalban-Bravo, Eitan Kugler, Wei-Ying Jen, Rita Khouri, Maro Ohanian, Rebecca Garris, Min Zhao, Guillermo Garcia-Manero, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1573.

https://doi.org/10.1182/blood-2025-1573

Published: 2025

Journal Articles

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study

Hannah Goulart, Elias Jabbour, Nitin Jain, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Kelly Chien, Fadi Haddad, Jayastu Senapati, Rita Khouri, Farhad Ravandi, Guillermo Garcia-Manero, Rebecca Garris, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2025-1571

Published: 2025

Journal Articles

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Hannah Goulart, Hagop Kantarjian, Nitin Jain, Rita Khouri, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alessandra Ferrajoli, Alex Bataller, Fadi Haddad, Jayastu Senapati, Guillermo Garcia-Manero, Rebecca Garris, Farhad Ravandi, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2025-1567

Published: 2025

Journal Articles

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Hannah Goulart, Hagop Kantarjian, Koji Sasaki, Nitin Jain, Caitlin Rausch, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Danielle Hammond, Mahesh Swaminathan, Rita Khouri, Maro Ohanian, Rebecca Garris, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2025-1566

Published: 2025

Journal Articles

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2025-1556

Published: 2025

Journal Articles

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Grace Park, Hagop Kantarjian, Nicholas Short, Nitin Jain, Farhad Ravandi, Kelly Chien, Jayastu Senapati, Fadi Haddad, Rita Khouri, Tapan Kadia, Naval Daver, Courtney DiNardo, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Naveen Pemmaraju, Rebecca Garris, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2025-1544

Published: 2025

Journal Articles

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 7092.

https://doi.org/10.1182/blood-2025-7092

Published: 2025

Journal Articles

Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor

Fadi Haddad, Hagop Kantarjian, Sara Dellasala, Ghayas Issa, Tapan Kadia, Jayastu Senapati, Rita Khouri, Nicholas Short, Courtney DiNardo, Nitin Jain, Hussein Abbas, Kelly Chien, Anwesha Ray, Naveen Pemmaraju, Farhad Ravandi, Guillermo Garcia-Manero, Koji Sasaki, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5564.

https://doi.org/10.1182/blood-2025-5564

Published: 2025

Journal Articles

Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens

Sankalp Arora, Koji Sasaki, Nicholas Short, Nitin Jain, Farhad Ravandi, Fadi Haddad, Jayastu Senapati, Guillermo Montalban-Bravo, Alexandre Bazinet, Rita Khouri, Rebecca Garris, Hagop Kantarjian, Elias Jabbour

Blood (2025) 146 (Supplement 1): 759.

https://doi.org/10.1182/blood-2025-759

Published: 2025

Journal Articles

Condensed total skin electron beam therapy prior to allogeneic stem cell transplantation in patients with cutaneous T-cell lymphoma/sezary syndrome

Jillian Gunther, Auris Huen, Julia Dai, Swami Iyer, Carlos Torres-Cabala, Luis Fayad, Luis Malpica, Timothy Lin, Penny Fang, Susan Wu, Chelsea Pinnix, Jessie Xu, Ranjit Nair, Samer Srour, Rita Khouri, Jeremy Ramdial, Yago Nieto, Chitra Hosing, Bouthaina Dabaja

Blood (2025) 146 (Supplement 1): 3650.

https://doi.org/10.1182/blood-2025-3650

Published: 2025

Journal Articles

Safety and efficacy of carniospinal irradiation (CSI) before CAR T cell therapy in patients with acute lymphoblastic leukemia (ALL) with central nervous system (CNS) disease: A potential role for CSI beyond cell killing and into immune priming

Blood (2025) 146 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2025-3326

Published: 2025

Journal Articles

Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial

Fadi Haddad, Elias Jabbour, Ghayas Issa, Koji Sasaki, Rita Khouri, Alex Bataller, Jayastu Senapati, Tapan Kadia, Guillermo Montalban-Bravo, Naveen Pemmaraju, Anwesha Ray, Sara Dellasala, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2025-5565

Published: 2025

Journal Articles

Characteristics and Clinical Outcomes of Patients with Myeloid Malignancies and Cohesin Mutations

Maria Rita Khouri, Bofei Wang, Poorva Bindal, Sakiko Suzuki, Lloyd Hutchinson, Laurie K Pearson, Andrew Gillis-Smith, Jan Cerny, Muthalagu Ramanathan, Jonathan M. Gerber, Shyam Ajay Patel

Blood (2024) 144 (Supplement 1): 1553.

https://doi.org/10.1182/blood-2024-201680

Published: 2024

Journal Articles

The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-140003

Published: 2020

Journal Articles

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Blood (2020) 136 (Supplement 1): 23–25.

https://doi.org/10.1182/blood-2020-143400

Published: 2020

Journal Articles

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Ghayas C. Issa, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Jeffrey Skinner, MHA, Rita Khouri, Naveen Pemmaraju, MD, Patrice Nasnas, MD, Sara E Dellasala, BS, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-143023

Published: 2020

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib

Kiyomi Morita, MDPhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Koji Sasaki, MD, Nitin Jain, MD, Marina Konopleva, MD PhD, Nicholas J. Short, MD, Koichi Takahashi, MD PhD, Rita Khouri, Patrice Nasnas, MD, Courtney D. DiNardo, MD MSCE, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Guillermo Montalban Bravo, MD, Ghayas C. Issa, MD, Jorge E. Cortes, MD, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 46–48.

https://doi.org/10.1182/blood-2020-141230

Published: 2020

Journal Articles

Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-140590

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor

Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens

Condensed total skin electron beam therapy prior to allogeneic stem cell transplantation in patients with cutaneous T-cell lymphoma/sezary syndrome

Safety and efficacy of carniospinal irradiation (CSI) before CAR T cell therapy in patients with acute lymphoblastic leukemia (ALL) with central nervous system (CNS) disease: A potential role for CSI beyond cell killing and into immune priming

Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial

Characteristics and Clinical Outcomes of Patients with Myeloid Malignancies and Cohesin Mutations

The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors

Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib

Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only